Alector (ALEC) Total Non-Current Liabilities (2018 - 2026)
Alector's (ALEC) quarterly Total Non-Current Liabilities came in at $227.8 million in Q1 2026, down 27.07% year-on-year from $312.3 million in Q1 2025, and down 12.68% on a QoQ basis from $260.9 million in Q4 2025.
Alector (ALEC) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Total Non-Current Liabilities data on file, last reported at $227.8 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 27.07% year-over-year to $227.8 million in Q1 2026; TTM through Mar 2026 was $227.8 million, a 27.07% decrease from a year earlier, with the FY2025 full-year figure at $260.9 million, down 23.34% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $227.8 million, down from $260.9 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ALEC reached as high as $686.8 million in Q1 2022 and fell as low as $227.8 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $440.4 million across 5 years, with a median of $455.2 million in 2024.
- Across the five-year window, Total Non-Current Liabilities soared 223.37% in 2022 and sank 32.25% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $572.4 million in 2022, then retreated by 15.05% to $486.3 million in 2023, then sank by 30.03% to $340.3 million in 2024, then dropped by 23.34% to $260.9 million in 2025, then dropped by 12.68% to $227.8 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $227.8 million in Q1 2026, $260.9 million in Q4 2025, and $276.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Alector | 164.78 Mn | -41.74 Mn | - | 227.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227.76 Mn |
| Dec 31, 2025 | 260.85 Mn |
| Sep 30, 2025 | 276.13 Mn |
| Jun 30, 2025 | 283.80 Mn |
| Mar 31, 2025 | 312.30 Mn |
| Dec 31, 2024 | 340.27 Mn |
| Sep 30, 2024 | 395.86 Mn |
| Jun 30, 2024 | 418.93 Mn |
| Mar 31, 2024 | 455.21 Mn |
| Dec 31, 2023 | 486.30 Mn |
| Sep 30, 2023 | 508.94 Mn |
| Jun 30, 2023 | 511.53 Mn |
| Mar 31, 2023 | 564.43 Mn |
| Dec 31, 2022 | 572.45 Mn |
| Sep 30, 2022 | 583.70 Mn |
| Jun 30, 2022 | 600.92 Mn |
| Mar 31, 2022 | 686.76 Mn |
| Dec 31, 2021 | 513.78 Mn |
| Sep 30, 2021 | 518.18 Mn |
| Jun 30, 2021 | 212.44 Mn |